Update on pulmonary arterial hypertension research: proceedings from a meeting of experts

Vallerie McLaughlin, Matthew Bacchetta, David Badesch, Raymond Benza, Charles Burger, Kelly Chin, Robert Frantz, Adaani Frost, Anna Hemnes, Nick H. Kim, Erika B. Rosenzweig, Lewis Rubin

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Background: While pulmonary arterial hypertension (PAH) remains a progressive, symptomatic condition characterized by increased pulmonary vascular resistance, ultimately leading to right heart failure, great strides have been made in its understanding and treatment over the past two decades. Review: Continued research in pre-clinical, clinical, and health economic areas of research, in addition to registry analyses and technology advances, is critical for understanding the pathophysiology of the disease and devising the best ways to monitor and manage patients. On December 3, 2016, the latest pre-clinical, clinical, health economic outcome, and registry data on PAH was presented in a symposium sponsored by Actelion. This paper reviews the published research and insight into upcoming research that was presented at this interactive meeting.

Original languageEnglish (US)
Pages (from-to)263-273
Number of pages11
JournalCurrent Medical Research and Opinion
Issue number2
StatePublished - Feb 1 2018


  • Clinical
  • health economics
  • preclinical
  • proceedings
  • pulmonary arterial hypertension
  • registry
  • technology

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Update on pulmonary arterial hypertension research: proceedings from a meeting of experts'. Together they form a unique fingerprint.

Cite this